Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 6—June 2024
Research

Estimates of SARS-CoV-2 Hospitalization and Fatality Rates in the Prevaccination Period, United States

Isabel GriffinComments to Author , Jessica King1, B. Casey Lyons1, Alyson L. Singleton1, Xidong Deng, Beau B. Bruce, and Patricia M. Griffin
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (I. Griffin, J. King, B.C. Lyons, X. Deng, B.B. Bruce, P.M. Griffin); Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA (A.L. Singleton)

Main Article

Table 3

Case-hospitalization rates by age group and sex of patients with SARS-CoV-2 infections that met inclusion criteria for case hospitalization rate analysis, United States, 2020*

Age group, y Case-hospitalization rate including cases for which hospitalization status was not known,
counted as not hospitalized, %
Case-hospitalization rate among cases for which hospitalization status was known, %
Male sex Female sex Male sex Female sex
<1 5.2 4.9 6.9 6.4
1–4 1.3 1.1 1.7 1.4
5–14 0.6 0.6 0.8 0.8
15–24 0.7 1.1 1.0 1.5
25–34 1.6 2.2 2.2 3.0
35–44 3.0 2.6 4.2 3.6
45–54 5.3 4.1 7.5 5.6
55–64 9.4 7.1 13.2 9.9
65–74 18.5 14.3 24.9 19.3
75–84 30.1 22.5 39.7 30.8
>85 35.4 21.4 47.8 31.7
Missing† 1.4 1.6 2.5 2.4

*Data from 21 jurisdictions that met the study inclusion criteria, CDC line level surveillance dataset, accessed March 17, 2021, based on responses to the CDC 2019 Novel Coronavirus Case Report Form during May 1–December 1, 2020. Reports in which no response was provided about hospitalization were excluded from the rate calculation. †Missing indicates that the field was left blank.

Main Article

1These authors contributed equally to this article.

Page created: May 02, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external